BioCardia, Inc.
Close on Oct 19, 2026
- Market cap
- $10.85M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | – | $-0.21 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 24, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | $-0.24 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | $-0.40 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | $-0.59 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 26, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | $3.00K | $-0.88 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | $55.00K | $-0.09 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | After market close | – | – | – |
Press releases
Announcements BioCardia filed with the SEC
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
Other events · EX-99.1 to Form 8-K
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix ™ Catheter
Other events · EX-99.1 to Form 8-K
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
Other events · EX-99.1 to Form 8-K
BioCardia to Present CardiAMP Regulatory and Corporate Progress at
Other events · EX-99.1 to Form 8-K
BIOCARDIA ANNOUNCES FDA CONFIRMS HELIX TRANSENDOCARDIAL DELIVERY CATHETER MEETING MINUTES SUPPORTING FOLLOW-ON DE NOVO PRE-SUBMISSION FOR APPROVAL
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Announces $4.4 Million Financing
Other events · EX-99.1 to Form 8-K
FDA CONFIRMS CARDIAMP HF II MAY SUPPORT PREMARKET APPROVAL OF CARDIAMP CELL THERAPY FOR ISCHEMIC HFrEF
Regulation FD disclosure · EX-99.1 to Form 8-K
BIOCARDIA ANNOUNCES JAPAN PMDA RECORD OF ADVICE SUPPORTS REGULATORY SUBMISSION FOR APPROVAL OF CARDIAMP CELL THERAPY FOR ISCHEMIC HEART FAILURE
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
BIOCARDIA AND FDA ALIGN ON HELIX TRANSENDOCARDIAL DELIVERY CATHETER CLEARANCE PATHWAYS
Regulation FD disclosure · EX-99.1 to Form 8-K
BIOCARDIA AND JAPAN PMDA ALIGN ON ACCEPTABILITY OF CARDIAMP CLINICAL DATA TO SUPPORT REGULATORY APPROVAL IN ISCHEMIC HEART FAILURE
Regulation FD disclosure · EX-99.1 to Form 8-K
BIOCARDIA FILES REQUEST FOR MEETING WITH FDA TO DISCUSS ACCELERATED APPROVAL PATHWAY FOR CARDIAMP ® SYSTEM IN ISCHEMIC HEART FAILURE
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Reports 2025 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA
Other events · EX-99.1 to Form 8-K
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
Other events · EX-99.1 to Form 8-K
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
Other events · EX-99.1 to Form 8-K
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
Other events · EX-99.1 to Form 8-K
BioCardia Regains Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
BioCardia Announces Pricing of Up To $12 Million Public Offering
Regulation FD disclosure · EX-99.1 to Form 8-K
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System
Other events · EX-99.1 to Form 8-K
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study
Other events · EX-99.1 to Form 8-K
BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company ’ s Lead Cell Therapy for Treatment of Heart Failure
Regulation FD disclosure · EX-99.1 to Form 8-K